Noelia Sabater-Cruz1,2, Marc Figueras-Roca3, Miriam Ferrán-Fuertes4, Elba Agustí5, Eva M Martínez-Conesa5, María Luisa Pérez-Rodríguez5, Anna Vilarrodona5, Ricardo P Casaroli-Marano3,5,6. 1. Hospital Clinic de Barcelona, Institut Clinic D'Oftalmologia (ICOF), Sabino de Arana s/n, 08028, Barcelona, Spain. Noelia.sabater@gmail.com. 2. Admiravisión, Institut Oftalmològic Integral, Barcelona, Spain. Noelia.sabater@gmail.com. 3. Hospital Clinic de Barcelona, Institut Clinic D'Oftalmologia (ICOF), Sabino de Arana s/n, 08028, Barcelona, Spain. 4. Hospital de la Creu Roja d'Hospitalet - Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain. 5. Barcelona Tissue Bank - Banc de Sang i Teixits (BTB), Barcelona, Spain. 6. Department of Surgery, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Abstract
PURPOSE: To study the indications and clinical outcomes, in a real-word setting, of amniotic membrane extract eye drops (AMEED) use for ocular surface disease (OSD). METHODS: A retrospective study of patients treated with topical AMEED between January 2018 and January 2020 was conducted. Patients were classified in two groups according to specific OSD-dry eye disease (DED) and wound healing delay (WHD) groups. Demographics, comorbidities, treatment duration and clinical outcomes were analysed. RESULTS: A total of 50 eyes of 36 patients with or without previous treatments were included. Patients in the DED group presented more systemic comorbidities (83 vs 22%; p < 0.001) and spent more mean time under AMEED treatment (10 vs 7.2 months average) than the WHD group (p = 0.0104). In four patients, long-term treatment (more than 24 months) was reported. Global similar symptomatic improvement was reported for both groups (DED 88.9% vs WHD 100%; p = 0.486), with the WHD group especially consisting in general relief (78%) and the DED group reporting more pain improvement (44%) (p = 0.011). Regarding patients with autologous serum as a previous treatment, no statistical differences were found in subjective or objective improvement. An overall success was achieved in 94.4% of the cases and no adverse events were found. CONCLUSION: AMEED administration is a promising mean to treat OSD such as dry eye, persistent epithelial defect and corneal ulcers. Although AMEED may be effective in the treatment of severe DED and persistent epithelial defect or corneal ulcers, conclusions are limited owing to the absence of controlled clinical trials.
PURPOSE: To study the indications and clinical outcomes, in a real-word setting, of amniotic membrane extract eye drops (AMEED) use for ocular surface disease (OSD). METHODS: A retrospective study of patients treated with topical AMEED between January 2018 and January 2020 was conducted. Patients were classified in two groups according to specific OSD-dry eye disease (DED) and wound healing delay (WHD) groups. Demographics, comorbidities, treatment duration and clinical outcomes were analysed. RESULTS: A total of 50 eyes of 36 patients with or without previous treatments were included. Patients in the DED group presented more systemic comorbidities (83 vs 22%; p < 0.001) and spent more mean time under AMEED treatment (10 vs 7.2 months average) than the WHD group (p = 0.0104). In four patients, long-term treatment (more than 24 months) was reported. Global similar symptomatic improvement was reported for both groups (DED 88.9% vs WHD 100%; p = 0.486), with the WHD group especially consisting in general relief (78%) and the DED group reporting more pain improvement (44%) (p = 0.011). Regarding patients with autologous serum as a previous treatment, no statistical differences were found in subjective or objective improvement. An overall success was achieved in 94.4% of the cases and no adverse events were found. CONCLUSION: AMEED administration is a promising mean to treat OSD such as dry eye, persistent epithelial defect and corneal ulcers. Although AMEED may be effective in the treatment of severe DED and persistent epithelial defect or corneal ulcers, conclusions are limited owing to the absence of controlled clinical trials.
Authors: Lyndon Jones; Laura E Downie; Donald Korb; Jose M Benitez-Del-Castillo; Reza Dana; Sophie X Deng; Pham N Dong; Gerd Geerling; Richard Yudi Hida; Yang Liu; Kyoung Yul Seo; Joseph Tauber; Tais H Wakamatsu; Jianjiang Xu; James S Wolffsohn; Jennifer P Craig Journal: Ocul Surf Date: 2017-07-20 Impact factor: 5.033
Authors: Marguerite B McDonald; Hosam Sheha; Sean Tighe; Susan B Janik; Frank W Bowden; Amit R Chokshi; Michael A Singer; Seema Nanda; Mujtaba A Qazi; Damon Dierker; Adam T Shupe; Brittany J McMurren Journal: Clin Ophthalmol Date: 2018-04-09
Authors: Michael S Murri; Majid Moshirfar; Orry C Birdsong; Yasmyne C Ronquillo; Yanning Ding; Phillip C Hoopes Journal: Clin Ophthalmol Date: 2018-06-18
Authors: Elizabeth Yeu; Damien F Goldberg; Francis S Mah; Kenneth A Beckman; Jodi I Luchs; Jonathan D Solomon; Darrell E White; Preeya K Gupta Journal: Clin Ophthalmol Date: 2019-05-27